secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001764013-26-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q3 net loss of $110.6M; cash $994.5M; D2T RA trial fully enrolled
--------------------------------------------------------------------------------

- Net loss $110.6M ($0.61/sh) for Q3 FY26; non-GAAP net loss $97.5M.
- Cash and equivalents $994.5M post-$550M financing; runway to GD commercial launch.
- D2T RA potentially registrational trial fully enrolled; topline data H2 2026.
- Batoclimab Phase 3 TED data expected H1 2026; IMVT-1402 GD and MG topline in 2027.
- R&D expenses $98.9M, up from $94.5M YoY; driven by IMVT-1402 clinical activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/0001764013-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/imvt-20260206.htm
  HTML page:      https://secwatch.observer/filing/0001764013-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer